Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant interferon alpha-1b · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | IFN weekly |
| Name | Type | Description |
|---|---|---|
| recombinant interferon alpha-1b | BIOLOGICAL | interferon |
| IFN | DRUG | IFN daily |
DISEASE CHARACTERISTICS: * Histologically confirmed malignancy, including, but not limited to, renal cell carcinoma, melanoma, Kaposi's sarcoma, breast carcinoma, lymphoma, myeloma, or tumors of endothelial origin * Stage IV disease * Refractory to standard therapy * Measurable or evaluable di...
Top 20 of 92 competitors
Recombinant interferon alpha-1b is an investigational biologic being studied for the treatment of breast cancer. It is a monoclonal antibody modality under development by Community Health Systems, Inc. (CYH). The drug is currently in Phase 1 clinical development for oncology indications, including breast cancer.
Recombinant interferon alpha-1b is a monoclonal antibody modality. Its specific molecular target has not been disclosed. The drug is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors, including breast cancer, to assess its safety and potential antitumor activity.
Recombinant interferon alpha-1b is being developed by Community Health Systems, Inc., which trades under the ticker CYH. The company is conducting clinical research on this investigational drug for oncology indications, including breast cancer.
Recombinant interferon alpha-1b is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, involving 35 patients with advanced solid tumors, lymphoma, or myeloma.
Recombinant interferon alpha-1b has one completed clinical trial, NCT00276536, titled 'Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma.' This Phase 1 study enrolled 35 patients in the United States and included conditions such as breast cancer, kidney cancer, lymphoma, melanoma, and multiple myeloma.
Recombinant interferon alpha-1b is a form of interferon alfa, as indicated by the clinical trial title 'Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma.' It is an investigational recombinant version of interferon alpha being studied for its antitumor effects in advanced cancers.